1-20 of 154
Koji Sasaki, MD
Close
Sort by
Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Andreas Hochhaus, MD, Carla Boquimpani, MD, Delphine Rea, MDPhD, Yosuke Minami, MDPhD, Elza Lomaia, MD PhD, Sergey Voloshin, MD PhD, Anna G. Turkina, Prof., MD, Dong-Wook Kim, MD, Jane Apperley, FRCP, FRCPath, MB, Jorge E. Cortes, MD, Andre Abdo, MD, Laura Maria Fogliatto, MD PhD, Dennis Dong Hwan Kim, MD PhD, Philipp D le Coutre, MD, Susanne Saussele, MD, Mario Annunziata, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Naeem A. Chaudhri, MD, Lynette C.Y. Chee, MBBS,PhDFRACP,FRCPA, Valentín García Gutiérrez, MD PhD, Koji Sasaki, MD, Paola Aimone, MD, Alex Allepuz, MD MPH, Sarah Quenet, Véronique Bédoucha, Michael J. Mauro, MD
Journal: Blood
Blood (2020) 136 (Supplement_2): LBA-4.
https://doi.org/10.1182/blood-2020-143816
Published: 2020
Journal Articles

Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia

Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Lucia Masarova, MD, Kiran Naqvi, MD MPH, Elias Jabbour, MD, Courtney D. DiNardo, MD MSCE, Koichi Takahashi, MD PhD, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Ghayas C. Issa, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Naval Daver, MD, Gautam Borthakur, MD, Zeev E. Estrov, MD, Joseph D. Khoury, MD, Sanam Loghavi, MD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur Patel, MD PhD, Srdan Verstovsek, MD PhD, Hagop M. Kantarjian, MD, Prithviraj Bose, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 54–56.
https://doi.org/10.1182/blood-2020-137176
Published: 2020
Journal Articles

The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis

Koji Sasaki, MD, Elias Jabbour, MD, Kiran Naqvi, MD MPH, Jeffrey Skinner, MHA, Kristin Anderson, Sara E Dellasala, BS, Musa Yilmaz, MD, Alessandra Ferrajoli, MD, Prithviraj Bose, MD, Philip A. Thompson, MB, MS, Yesid Alvarado, MD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Koichi Takahashi, MD PhD, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Rita Khouri, Shilpa Paul, PharmD, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–5.
https://doi.org/10.1182/blood-2020-140003
Published: 2020
Journal Articles

Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation

Danielle Hammond, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Jorge M. Ramos Perez, MD, Veronica A Guerra, MD, Rashmi Kanagal-Shamanna, MD, Shilpa Paul, PharmD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Naval Daver, MD, Zeev E. Estrov, MD, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban-Bravo, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-136385
Published: 2020
Journal Articles

Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study

Koji Sasaki, MD, Elias Jabbour, MD, Guillermo Montalban Bravo, MD, Nicholas J. Short, MD, Rashmi Kanagal-Shamanna, MD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Jorge E. Cortes, MD, Farhad Ravandi, MBBS, Yesid Alvarado, MD, Kelly S. Chien, MD, Hui Yang, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-139817
Published: 2020
Journal Articles

Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Lymphoblastic Leukemia (ALL)

Veronica A Guerra, MD, Yasmin Alwash, MD, Yan Yuanqing, PhD, Jorge M. Ramos Perez, MD, Guillaume Richard-Carpentier, MD, Ahmad S. Alotaibi, MD, Hycienth O Ahaneku, MD MPH, PhD, Bachar Samra, MD, Arrvind Raghunath, MD, Nitin Jain, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Alessandra Ferrajoli, MD, Koji Sasaki, MD, Steven M. Kornblau, MD, Zeev E. Estrov, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-142055
Published: 2020
Journal Articles

Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis

Kiyomi Morita, MDPhD, Koji Sasaki, MD, Guillaume Richard-Carpentier, MD, Marina Konopleva, MD PhD, Xuelin Huang, PhD, Nicholas J. Short, MD, Nitin Jain, MD, Farhad Ravandi, MBBS, Bouthaina S. Dabaja, MD, Naval Daver, MD, Tapan M. Kadia, MD, Yesid Alvarado, MD, Courtney D. DiNardo, MD MSCE, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD PhD, Sa A Wang, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Richard E. Champlin, MD, Issa F. Khouri, MD, Partow Kebriaei, MD, Heather M. Schroeder, Maria Khouri, Koichi Takahashi, MD PhD, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-142121
Published: 2020
Journal Articles

Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma

Hussein A Abbas, MDPhD, Patrick K Reville, MD, Alexis Geppner, Maro Ohanian, DO, Koji Sasaki, MD, Gautam Borthakur, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Carlos E. Bueso-Ramos, MD PhD, Michael Andreeff, MD PhD, Nicholas J. Short, MD, Sherry A. Pierce, BSN, BA, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-138459
Published: 2020
Journal Articles

Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure

Veronia Guerra, Jorge M. Ramos Perez, MD, Danielle Hammond, MD, Kelly S. Chien, MD, Rashmi Kanagal-Shamanna, MD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Shilpa Paul, PharmD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Naval Daver, MD, Farhad Ravandi, MBBS, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Ghayas C. Issa, MD, Koichi Takahashi, MD PhD, Zeev E. Estrov, MD, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban Bravo, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-139901
Published: 2020
Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Naval Daver, MD, Hind Rafei, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Maria R Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-139896
Published: 2020
Journal Articles

A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Hind Rafei, MD, Sa A Wang, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Maria Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–4.
https://doi.org/10.1182/blood-2020-140037
Published: 2020
Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Yesid Alvarado, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Serena Chew, PharmD, Guillermo Garcia-Manero, MD, Jan A. Burger, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Maro Ohanian, DO, Maria Khouri, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–38.
https://doi.org/10.1182/blood-2020-143386
Published: 2020
Journal Articles

Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Richard E. Champlin, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Nadya Jammal, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Rita Khouri, Patrice Nasnas, MD, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
https://doi.org/10.1182/blood-2020-143286
Published: 2020
Journal Articles

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, C. Cameron Yin, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Koichi Takahashi, MD PhD, Bouthaina S. Dabaja, MD, Srdan Verstovsek, MD PhD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Caitlin R. Rausch, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Patrice Nasnas, MD, Rita Khouri, Monica Kwari, BSN, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–47.
https://doi.org/10.1182/blood-2020-143401
Published: 2020
Journal Articles

Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia

Nicholas J. Short, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Koji Sasaki, MD, Ghayas C. Issa, MD, Guillermo Montalban-Bravo, MD, Prithviraj Bose, MD, Jan A. Burger, MD PhD, Darla Miller, Lynette Alexander-Williams, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Naval Daver, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–23.
https://doi.org/10.1182/blood-2020-140153
Published: 2020
Journal Articles

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban Bravo, MD, Panagiotis Katsonis, Koji Sasaki, MD, Caleb Class, PhD, Christopher B. Benton, MD, Elias Jabbour, MD, Kelly S. Chien, MD, Rajyalakshmi Luthra, PhD, Carlos E. Bueso-Ramos, MD PhD, Tapan M. Kadia, MD, Michael Andreeff, MD PhD, Nicholas J. Short, MD, Naval Daver, MD, Mark Routbort, MD PhD, Joseph D. Khoury, MD, Keyur Patel, MD PhD, Irene Ganan-Gomez, PhD, Yue Wei, PhD, Gautam Borthakur, MD, Farhad Ravandi, MBBS, Kim-Anh Do, PhD, Kelly A. Soltysiak, PhD, Olivier Lichtarge, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-141411
Published: 2020
Journal Articles

A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)

Kiyomi Morita, MDPhD, Hagop M. Kantarjian, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Naval Daver, MD, Elias Jabbour, MD, Yesid Alvarado, MD, Kelly S. Chien, MD, Courtney D. DiNardo, MD MSCE, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Kiran Naqvi, MD MPH, Jorge E. Cortes, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Caitlin R. Rausch, PharmD, Yvonne Gasior, RN, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–9.
https://doi.org/10.1182/blood-2020-142003
Published: 2020
Journal Articles

Impact of Hemoglobin Level As a Continuous Variable in Calculating Prognosis in MDS: Incorporation into LSC4 and IPSS-R

Faezeh Darbaniyan, PhD, Guillermo Montalban Bravo, MD, Yue Wei, PhD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Hui Yang, MD PhD, Kelly A. Soltysiak, PhD, Kelly S. Chien, MD, Kim-Anh Do, PhD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-140029
Published: 2020
Journal Articles

Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression

Kiyomi Morita, MDPhD, Hagop M. Kantarjian, MD, Hong Fang, MD, Farhad Ravandi, MBBS, Nitin Jain, MD, Marina Konopleva, MD PhD, El Hussein Siba, MD, Feng Wang, PhD, Nicholas J. Short, MD, Koichi Takahashi, MD PhD, Rita Khouri, Koji Sasaki, MD, Courtney D. DiNardo, MD MSCE, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Guillermo Montalban Bravo, MD, Sergej Konoplev, MD PhD, Joseph D. Khoury, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–40.
https://doi.org/10.1182/blood-2020-140590
Published: 2020
Journal Articles

Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)

Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Faezeh Darbaniyan, PhD, Irene Ganan-Gomez, PhD, Koji Sasaki, MD, Kiran Naqvi, MD MPH, Yue Wei, PhD, Hui Yang, MD PhD, Kelly A. Soltysiak, PhD, Kelly S. Chien, MD, Carlos E. Bueso-Ramos, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-139983
Published: 2020